vs

Side-by-side financial comparison of Amplitude, Inc. (AMPL) and MEDIFAST INC (MED). Click either name above to swap in a different company.

Amplitude, Inc. is the larger business by last-quarter revenue ($91.4M vs $75.1M, roughly 1.2× MEDIFAST INC). On growth, Amplitude, Inc. posted the faster year-over-year revenue change (17.0% vs -36.9%). Amplitude, Inc. produced more free cash flow last quarter ($12.7M vs $-6.6M). Over the past eight quarters, Amplitude, Inc.'s revenue compounded faster (12.2% CAGR vs -34.4%).

Amplitude is an American publicly traded company that develops digital analytics software. The company was listed publicly on the Nasdaq stock exchange under the ticker symbol AMPL on September 28, 2021.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

AMPL vs MED — Head-to-Head

Bigger by revenue
AMPL
AMPL
1.2× larger
AMPL
$91.4M
$75.1M
MED
Growing faster (revenue YoY)
AMPL
AMPL
+53.9% gap
AMPL
17.0%
-36.9%
MED
More free cash flow
AMPL
AMPL
$19.3M more FCF
AMPL
$12.7M
$-6.6M
MED
Faster 2-yr revenue CAGR
AMPL
AMPL
Annualised
AMPL
12.2%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AMPL
AMPL
MED
MED
Revenue
$91.4M
$75.1M
Net Profit
$-17.7M
Gross Margin
74.6%
69.4%
Operating Margin
-18.3%
-10.4%
Net Margin
-19.3%
Revenue YoY
17.0%
-36.9%
Net Profit YoY
45.8%
EPS (diluted)
$-0.13
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMPL
AMPL
MED
MED
Q4 25
$91.4M
$75.1M
Q3 25
$88.6M
$89.4M
Q2 25
$83.3M
$105.6M
Q1 25
$80.0M
$115.7M
Q4 24
$78.1M
$119.0M
Q3 24
$75.2M
$140.2M
Q2 24
$73.3M
$168.6M
Q1 24
$72.6M
$174.7M
Net Profit
AMPL
AMPL
MED
MED
Q4 25
$-17.7M
Q3 25
$-24.0M
$-2.3M
Q2 25
$-24.7M
$2.5M
Q1 25
$-22.2M
$-772.0K
Q4 24
$-32.6M
Q3 24
$-16.9M
$1.1M
Q2 24
$-23.4M
$-8.2M
Q1 24
$-21.5M
$8.3M
Gross Margin
AMPL
AMPL
MED
MED
Q4 25
74.6%
69.4%
Q3 25
73.9%
69.5%
Q2 25
72.6%
72.6%
Q1 25
74.7%
72.8%
Q4 24
74.7%
74.1%
Q3 24
75.1%
75.4%
Q2 24
73.4%
73.2%
Q1 24
74.0%
72.8%
Operating Margin
AMPL
AMPL
MED
MED
Q4 25
-18.3%
-10.4%
Q3 25
-26.0%
-4.6%
Q2 25
-29.0%
-1.0%
Q1 25
-26.8%
-1.1%
Q4 24
-41.2%
0.6%
Q3 24
-21.4%
1.5%
Q2 24
-31.7%
-4.7%
Q1 24
-29.0%
4.5%
Net Margin
AMPL
AMPL
MED
MED
Q4 25
-19.3%
Q3 25
-27.1%
-2.5%
Q2 25
-29.6%
2.3%
Q1 25
-27.8%
-0.7%
Q4 24
-41.7%
Q3 24
-22.4%
0.8%
Q2 24
-31.9%
-4.8%
Q1 24
-29.5%
4.8%
EPS (diluted)
AMPL
AMPL
MED
MED
Q4 25
$-0.13
$-1.64
Q3 25
$-0.18
$-0.21
Q2 25
$-0.19
$0.22
Q1 25
$-0.17
$-0.07
Q4 24
$-0.25
$0.08
Q3 24
$-0.14
$0.10
Q2 24
$-0.19
$-0.75
Q1 24
$-0.18
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMPL
AMPL
MED
MED
Cash + ST InvestmentsLiquidity on hand
$192.0M
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$245.3M
$198.9M
Total Assets
$420.7M
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMPL
AMPL
MED
MED
Q4 25
$192.0M
$167.3M
Q3 25
$189.2M
$173.5M
Q2 25
$208.1M
$162.7M
Q1 25
$209.0M
$164.6M
Q4 24
$241.1M
$162.3M
Q3 24
$319.9M
$170.0M
Q2 24
$318.3M
$163.5M
Q1 24
$316.1M
$156.4M
Stockholders' Equity
AMPL
AMPL
MED
MED
Q4 25
$245.3M
$198.9M
Q3 25
$262.2M
$214.7M
Q2 25
$279.5M
$216.0M
Q1 25
$289.5M
$211.0M
Q4 24
$296.6M
$210.1M
Q3 24
$290.0M
$207.3M
Q2 24
$287.3M
$205.3M
Q1 24
$289.2M
$211.0M
Total Assets
AMPL
AMPL
MED
MED
Q4 25
$420.7M
$248.0M
Q3 25
$438.1M
$268.2M
Q2 25
$456.6M
$269.3M
Q1 25
$445.8M
$280.0M
Q4 24
$445.9M
$284.2M
Q3 24
$445.6M
$291.2M
Q2 24
$445.4M
$293.5M
Q1 24
$437.9M
$302.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMPL
AMPL
MED
MED
Operating Cash FlowLast quarter
$12.8M
$-5.3M
Free Cash FlowOCF − Capex
$12.7M
$-6.6M
FCF MarginFCF / Revenue
13.8%
-8.8%
Capex IntensityCapex / Revenue
0.2%
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$28.2M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMPL
AMPL
MED
MED
Q4 25
$12.8M
$-5.3M
Q3 25
$5.0M
$12.1M
Q2 25
$20.1M
$-3.4M
Q1 25
$-8.0M
$3.4M
Q4 24
$3.2M
$-4.9M
Q3 24
$6.2M
$9.1M
Q2 24
$9.2M
$13.1M
Q1 24
$-48.0K
$7.3M
Free Cash Flow
AMPL
AMPL
MED
MED
Q4 25
$12.7M
$-6.6M
Q3 25
$4.5M
$10.8M
Q2 25
$19.5M
$-4.8M
Q1 25
$-8.5M
$1.9M
Q4 24
$2.4M
$-7.2M
Q3 24
$6.2M
$7.7M
Q2 24
$8.6M
$11.1M
Q1 24
$-405.0K
$5.4M
FCF Margin
AMPL
AMPL
MED
MED
Q4 25
13.8%
-8.8%
Q3 25
5.1%
12.0%
Q2 25
23.4%
-4.5%
Q1 25
-10.6%
1.6%
Q4 24
3.1%
-6.1%
Q3 24
8.2%
5.5%
Q2 24
11.8%
6.6%
Q1 24
-0.6%
3.1%
Capex Intensity
AMPL
AMPL
MED
MED
Q4 25
0.2%
1.8%
Q3 25
0.5%
1.5%
Q2 25
0.6%
1.3%
Q1 25
0.5%
1.3%
Q4 24
1.0%
1.9%
Q3 24
0.0%
1.0%
Q2 24
0.8%
1.1%
Q1 24
0.5%
1.1%
Cash Conversion
AMPL
AMPL
MED
MED
Q4 25
Q3 25
Q2 25
-1.36×
Q1 25
Q4 24
Q3 24
8.04×
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMPL
AMPL

US$55.8M61%
International$35.7M39%

MED
MED

Segment breakdown not available.

Related Comparisons